188 related articles for article (PubMed ID: 17616113)
1. Design and synthesis of a new class of selective integrin alpha5beta1 antagonists.
Stragies R; Osterkamp F; Zischinsky G; Vossmeyer D; Kalkhof H; Reimer U; Zahn G
J Med Chem; 2007 Aug; 50(16):3786-94. PubMed ID: 17616113
[TBL] [Abstract][Full Text] [Related]
2. Rational design of highly active and selective ligands for the alpha5beta1 integrin receptor.
Heckmann D; Meyer A; Laufer B; Zahn G; Stragies R; Kessler H
Chembiochem; 2008 Jun; 9(9):1397-407. PubMed ID: 18481343
[TBL] [Abstract][Full Text] [Related]
3. Multiple N-methylation by a designed approach enhances receptor selectivity.
Chatterjee J; Ovadia O; Zahn G; Marinelli L; Hoffman A; Gilon C; Kessler H
J Med Chem; 2007 Nov; 50(24):5878-81. PubMed ID: 17973471
[TBL] [Abstract][Full Text] [Related]
4. Probing integrin selectivity: rational design of highly active and selective ligands for the alpha5beta1 and alphavbeta3 integrin receptor.
Heckmann D; Meyer A; Marinelli L; Zahn G; Stragies R; Kessler H
Angew Chem Int Ed Engl; 2007; 46(19):3571-4. PubMed ID: 17394271
[No Abstract] [Full Text] [Related]
5. Antiangiogenic effect of dual/selective alpha(5)beta(1)/alpha(v)beta(3) integrin antagonists designed on partially modified retro-inverso cyclotetrapeptide mimetics.
Gentilucci L; Cardillo G; Spampinato S; Tolomelli A; Squassabia F; De Marco R; Bedini A; Baiula M; Belvisi L; Civera M
J Med Chem; 2010 Jan; 53(1):106-18. PubMed ID: 20055426
[TBL] [Abstract][Full Text] [Related]
6. Ligand binding analysis for human alpha5beta1 integrin: strategies for designing new alpha5beta1 integrin antagonists.
Marinelli L; Meyer A; Heckmann D; Lavecchia A; Novellino E; Kessler H
J Med Chem; 2005 Jun; 48(13):4204-7. PubMed ID: 15974570
[TBL] [Abstract][Full Text] [Related]
7. Discovery of orally available integrin alpha5beta1 antagonists.
Zischinsky G; Osterkamp F; Vossmeyer D; Zahn G; Scharn D; Zwintscher A; Stragies R
Bioorg Med Chem Lett; 2010 Jan; 20(1):380-2. PubMed ID: 19910191
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of non-peptide alpha(v)beta(3)/alpha(5)beta(1) integrin dual antagonists containing 5,6-dihydropyridin-2-one scaffolds.
Benfatti F; Cardillo G; Fabbroni S; Galzerano P; Gentilucci L; Juris R; Tolomelli A; Baiula M; Spartà A; Spampinato S
Bioorg Med Chem; 2007 Dec; 15(23):7380-90. PubMed ID: 17869121
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel short chain 4-substituted indoles as potent alphavbeta3 antagonist using structure-based drug design.
Raboisson P; Desjarlais RL; Reed R; Lattanze J; Chaikin M; Manthey CL; Tomczuk BE; Marugán JJ
Eur J Med Chem; 2007 Mar; 42(3):334-43. PubMed ID: 17184884
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacophore model of integrin alphavbeta3 antagonists].
Cheng GY; Ni GH; Jiang FC
Yao Xue Xue Bao; 2009 Apr; 44(4):379-85. PubMed ID: 19545055
[TBL] [Abstract][Full Text] [Related]
11. SAR of N-phenyl piperidine based oral integrin alpha5beta1 antagonists.
Zischinsky G; Osterkamp F; Vossmeyer D; Zahn G; Scharn D; Zwintscher A; Stragies R
Bioorg Med Chem Lett; 2010 Jan; 20(1):65-8. PubMed ID: 19959360
[TBL] [Abstract][Full Text] [Related]
12. Pharmacophoric modifications lead to superpotent αvβ3 integrin ligands with suppressed α5β1 activity.
Neubauer S; Rechenmacher F; Brimioulle R; Di Leva FS; Bochen A; Sobahi TR; Schottelius M; Novellino E; Mas-Moruno C; Marinelli L; Kessler H
J Med Chem; 2014 Apr; 57(8):3410-7. PubMed ID: 24654918
[TBL] [Abstract][Full Text] [Related]
13. Tricyclic pharmacophore-based molecules as novel integrin alphavbeta3 antagonists. Part IV: preliminary control of alphavbeta3 selectivity by meta-oriented substitution.
Kubota D; Ishikawa M; Ishikawa M; Yahata N; Murakami S; Fujishima K; Kitakaze M; Ajito K
Bioorg Med Chem; 2006 Jun; 14(12):4158-81. PubMed ID: 16504518
[TBL] [Abstract][Full Text] [Related]
14. Single cell tracking assay reveals an opposite effect of selective small non-peptidic α5β1 or αvβ3/β5 integrin antagonists in U87MG glioma cells.
Ray AM; Schaffner F; Janouskova H; Noulet F; Rognan D; Lelong-Rebel I; Choulier L; Blandin AF; Lehmann M; Martin S; Kapp T; Neubauer S; Rechenmacher F; Kessler H; Dontenwill M
Biochim Biophys Acta; 2014 Sep; 1840(9):2978-87. PubMed ID: 24810979
[TBL] [Abstract][Full Text] [Related]
15. Heterocyclic 1,7-disubstituted indole sulfonamides are potent and selective human EP3 receptor antagonists.
Hategan G; Polozov AM; Zeller W; Cao H; Mishra RK; Kiselyov AS; Ramirez J; Halldorsdottir G; Andrésson T; Gurney ME; Singh J
Bioorg Med Chem Lett; 2009 Dec; 19(23):6797-800. PubMed ID: 19836233
[TBL] [Abstract][Full Text] [Related]
16. Functionalizing αvβ3- or α5β1-selective integrin antagonists for surface coating: a method to discriminate integrin subtypes in vitro.
Rechenmacher F; Neubauer S; Polleux J; Mas-Moruno C; De Simone M; Cavalcanti-Adam EA; Spatz JP; Fässler R; Kessler H
Angew Chem Int Ed Engl; 2013 Jan; 52(5):1572-5. PubMed ID: 23345131
[No Abstract] [Full Text] [Related]
17. Discovery of 5-arylsulfonamido-3-(pyrrolidin-2-ylmethyl)-1H-indole derivatives as potent, selective 5-HT6 receptor agonists and antagonists.
Cole DC; Lennox WJ; Lombardi S; Ellingboe JW; Bernotas RC; Tawa GJ; Mazandarani H; Smith DL; Zhang G; Coupet J; Schechter LE
J Med Chem; 2005 Jan; 48(2):353-6. PubMed ID: 15658848
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and PKCtheta inhibitory activity of a series of 5-vinyl phenyl sulfonamide-3-pyridinecarbonitriles.
Shim J; Eid C; Lee J; Liu E; Chaudhary D; Boschelli DH
Bioorg Med Chem Lett; 2009 Dec; 19(23):6575-7. PubMed ID: 19854645
[TBL] [Abstract][Full Text] [Related]
19. Discovery of small molecule integrin alphavbeta3 antagonists as novel anticancer agents.
Dayam R; Aiello F; Deng J; Wu Y; Garofalo A; Chen X; Neamati N
J Med Chem; 2006 Jul; 49(15):4526-34. PubMed ID: 16854058
[TBL] [Abstract][Full Text] [Related]
20. Tricyclic pharmacophore-based molecules as novel integrin alpha(v)beta3 antagonists. Part 1: design and synthesis of a lead compound exhibiting alpha(v)beta3/alpha(IIb)beta3 dual antagonistic activity.
Kubota D; Ishikawa M; Yamamoto M; Murakami S; Hachisu M; Katano K; Ajito K
Bioorg Med Chem; 2006 Apr; 14(7):2089-108. PubMed ID: 16309911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
